利波迪西兰是一种延长时间的短干扰RNA向脂蛋白:一个随机剂量上升的临床试验
Steven E Nissen1, Helle Linnebjerg2, Xi Shen2
1Cleveland Clinic Center for Clinical Research, Cleveland, Ohio.
JAMA
|November 12, 2023
概括
利波迪西兰是一种新型RNA干扰疗法,在1期试验中显著降低了脂蛋白水平. 这种试验药物耐受性良好,具有剂量依赖和长期的效果,支持进一步的临床评估,以减少心血管风险.
科学领域:
- 心血管医学
- 药理学
- 有关RNA疗法
背景情况:
- 血脂蛋白升高是动脉样硬化和大动脉狭窄的遗传风险因素.
- 目前降低脂蛋白的治疗选择有限,突出显示需要新的药物干预措施.
研究的目的:
- 评估勒波迪西兰的安全性,耐受性,药理动力学和疗效,一个短干扰RNA向阿波脂蛋白 (a) 合成,在具有高脂蛋白 (a) 的个体中.
- 评估单次服用莱波迪西兰对血清脂蛋白度的影响.
主要方法:
- 一个单剂量上升,随机,安慰剂对照的第一阶段试验,涉及48名脂肪蛋白水平升高的成年人.
- 参与者接受了4毫克至608毫克的皮下安慰剂或勒波迪西兰剂量.
- 安全性,耐受性,血勒波迪西兰度以及脂蛋白度的变化被监测了长达336天.
主要成果:
- 在所有测试剂量中,勒波迪西兰的耐受性一般很好.
- 药物动力学分析显示,勒波迪西兰的血水平在10. 5小时内达到峰值,并在48小时内无法检测到.
- 观察到与剂量相关的脂蛋白降低,最高剂量 (608 mg) 在第337天达到中位数降低97%.
结论:
- 单剂量莱波迪西兰在患有高脂蛋白的个体中显示出良好的安全性和耐受性.
- 药物诱导了显著的,剂量依赖的,长期持续的血清脂蛋白度降低.
- 这些发现为进一步研究心血管风险管理的临床试验提供了强有力的理由.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
674
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
674
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191